{"DataElement":{"publicId":"6091664","version":"1","preferredName":"Treatment Cohort Study 10150 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10150 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_10150_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6091429","version":"1","preferredName":"10150 Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"6091429v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"SG5","valueDescription":"SG5: Platinum Refractory, Prior Bevacizumab, No","ValueMeaning":{"publicId":"6098646","version":"1","preferredName":"SG5: Platinum Refractory, Prior Bevacizumab, No","longName":"6098646","preferredDefinition":"SG5: Platinum Refractory, Prior Bevacizumab, No","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"665FDF9A-527D-0F00-E053-F662850A1C16","latestVersionIndicator":"Yes","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"665FDF9A-5296-0F00-E053-F662850A1C16","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","deletedIndicator":"No"},{"value":"SG4","valueDescription":"SG4: Platinum Refractory, Prior Bevacizumab Yes","ValueMeaning":{"publicId":"6098647","version":"1","preferredName":"SG4: Platinum Refractory, Prior Bevacizumab Yes","longName":"6098647","preferredDefinition":"SG4: Platinum Refractory, Prior Bevacizumab Yes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"665FDF9A-52A0-0F00-E053-F662850A1C16","latestVersionIndicator":"Yes","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"665FDF9A-52B9-0F00-E053-F662850A1C16","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","deletedIndicator":"No"},{"value":"SG3","valueDescription":"SG3: Platinum Resistant, Prior Bevacizumab, No","ValueMeaning":{"publicId":"6098648","version":"1","preferredName":"SG3: Platinum Resistant, Prior Bevacizumab, No","longName":"6098648","preferredDefinition":"SG3: Platinum Resistant, Prior Bevacizumab, No","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"665FDF9A-52C3-0F00-E053-F662850A1C16","latestVersionIndicator":"Yes","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"665FDF9A-52DC-0F00-E053-F662850A1C16","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","deletedIndicator":"No"},{"value":"SG1","valueDescription":"SG1: Phase I","ValueMeaning":{"publicId":"6098650","version":"1","preferredName":"SG1: Phase I","longName":"6098650","preferredDefinition":"SG1: Phase I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"665FDF9A-5309-0F00-E053-F662850A1C16","latestVersionIndicator":"Yes","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"665FDF9A-5322-0F00-E053-F662850A1C16","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","deletedIndicator":"No"},{"value":"SG2","valueDescription":"SG2: Platinum Resistant, Prior Bevacizumab Yes","ValueMeaning":{"publicId":"6098649","version":"1","preferredName":"SG2: Platinum Resistant, Prior Bevacizumab Yes","longName":"6098649","preferredDefinition":"SG2: Platinum Resistant, Prior Bevacizumab Yes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"665FDF9A-52E6-0F00-E053-F662850A1C16","latestVersionIndicator":"Yes","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"665FDF9A-52FF-0F00-E053-F662850A1C16","beginDate":"2018-03-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-01","modifiedBy":"ONEDATA","dateModified":"2018-03-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6635928E-5E21-479B-E053-F662850A67CB","latestVersionIndicator":"Yes","beginDate":"2018-02-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-27","modifiedBy":"SOKKERL","dateModified":"2018-09-13","changeDescription":"4/13/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Subgroup","type":"Preferred Question Text","description":"Subgroup","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6636E93E-462A-4793-E053-F662850AAD33","latestVersionIndicator":"Yes","beginDate":"2018-02-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-27","modifiedBy":"SOKKERL","dateModified":"2018-09-13","changeDescription":"2/27/28 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}